Efficace Fabio, Patriarca Andrea, Luppi Mario, Potenza Leonardo, Caocci Giovanni, Tafuri Agostino, Fazio Francesca, Cartoni Claudio, Petrucci Maria Teresa, Carmosino Ida, Moia Riccardo, Margiotta Casaluci Gloria, Boggione Paola, Colaci Elisabetta, Giusti Davide, Pioli Valeria, Sparano Francesco, Cottone Francesco, De Fabritiis Paolo, Ardu Nicolina Rita, Niscola Pasquale, Capodanno Isabella, Leporace Anna Paola, Pelliccia Sabrina, Lugli Elisabetta, La Sala Edoardo, Rigacci Luigi, Santopietro Michelina, Fozza Claudio, Siragusa Sergio, Breccia Massimo, Fazi Paola, Vignetti Marco
Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy.
Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Front Oncol. 2022 Mar 17;12:826040. doi: 10.3389/fonc.2022.826040. eCollection 2022.
Digital health tools are increasingly being used in cancer care and may include electronic patient-reported outcome (ePRO) monitoring systems. We examined physicians' perceptions of usability and clinical utility of a digital health tool (GIMEMA-ALLIANCE platform) for ePRO monitoring in the real-life practice of patients with hematologic malignancies. This tool allows for the collection and assessment of ePROs with real-time graphical presentation of results to medical staff. Based on a predefined algorithm, automated alerts are sent to medical staff. Participating hematologists completed an online survey on their experience with the platform. Of the 201 patients invited to participate between December 2020 and June 2021 (cut-off date for current analysis), 180 (90%) agreed to enter the platform and had a median age of 57 years. Twenty-three hematologists with a median age of 42 years and an average of 17 years of experience in clinical practice were surveyed. All hematologists agreed or strongly agreed that the platform was easy to use, and 87%, agreed or strongly agreed that ePROs data were useful to enhance communication with their patients. The majority of physicians (78%) accessed the platform at least once per month to consult the symptom and health status profile of their patients. The frequency of access was independent of physician sex (=0.393) and years of experience in clinical practice (=0.404). In conclusion, our preliminary results support the clinical utility, from the perspective of the treating hematologist, of integrating ePROs into the routine cancer care of patients with hematologic malignancies.
数字健康工具在癌症护理中的应用日益广泛，可能包括电子患者报告结局（ePRO）监测系统。我们研究了医生对一种用于血液系统恶性肿瘤患者实际临床实践中ePRO监测的数字健康工具（GIMEMA-ALLIANCE平台）的可用性和临床实用性的看法。该工具能够收集和评估ePRO，并将结果实时以图形方式呈现给医护人员。基于预定义算法，会向医护人员发送自动警报。参与研究的血液科医生完成了一项关于他们使用该平台体验的在线调查。在2020年12月至2021年6月（当前分析的截止日期）期间邀请参与的201名患者中，180名（90%）同意进入该平台，他们的中位年龄为57岁。对23名中位年龄为42岁、平均临床实践经验为17年的血液科医生进行了调查。所有血液科医生都同意或强烈同意该平台易于使用，87%的医生同意或强烈同意ePRO数据有助于加强与患者的沟通。大多数医生（占78%）每月至少访问一次该平台，以查看其患者的症状和健康状况概况。访问频率与医生性别（P=0.393）和临床实践经验年限（P=0.404）无关。总之，我们的初步结果从主治血液科医生的角度支持了将ePRO整合到血液系统恶性肿瘤患者常规癌症护理中的临床实用性。
